Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model

Circulation: Cardiovascular Imaging

Volumn 3, Issue 5, 2010, Pages 550-558

  Lightfoot, James C ^a   D'Agostino Jr , Ralph B ^a   Hamilton, Craig A ^a   Jordan, Jennifer ^a   Torti, Frank M ^a   Kock, Nancy D ^a   Jordan, James ^a   Workman, Susan ^a   Hundley, W Gregory ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Cardiotoxicity; Chemotherapy; Congestive heart failure; Doxorubicin

Indexed keywords

DOXORUBICIN; GADOLINIUM; GADOTERIDOL; ANTINEOPLASTIC ANTIBIOTIC; CONTRAST MEDIUM; DIAGNOSTIC AGENT; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CELL VACUOLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EARLY DIAGNOSIS; EXPERIMENTAL MODEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HISTOPATHOLOGY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; ANIMAL; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DOXORUBICIN; EARLY DIAGNOSIS; HETEROCYCLIC COMPOUNDS; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; RATS; STROKE VOLUME; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 77957367762     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.109.918540     Document Type: Article

References (20)

1. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339: 974-984. (Pubitemid 28455101)
2. Leandro J, Dyck J, Poppe D, Shore R, Airhart C, Greenberg M, Gilday D, Smallhorn J, Benson L. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol. 1994;74:1152-1156. (Pubitemid 24366518)
3. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH, Schwartz DE, Bacharach SL, Green MV, Rosenberg SA. Doxorubicin cardiotoxicity: Assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med. 1981;94:430-435. (Pubitemid 11103937)
4. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol. 2005;23:8597-8605. (Pubitemid 46211501)
5. DeVita VT. Cancer Principles and Practice of Oncology, 4th ed. Lippincott; Philadelphia, Pa: 1993.
6. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-1453.
7. Hundley WG, Kizilbash AM, Afridi I, Franco F, Peshock RM, Grayburn PA. Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: Comparison with cine magnetic resonance imaging. J Am Coll Cardiol. 1998;32:1426-1432.
8. Chuang ML, Hibberd MG, Salton CJ, Beaudin RA, Riley MF, Parker RA, Douglas PS, Manning WJ. Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: Assessment by two- and three-dimensional echocardiography and magnetic resonance imaging. J Am Coll Cardiol. 2000;35: 477-484. (Pubitemid 30125541)
9. Hundley WG, Li HF, Willard JE, Landau C, Lange RA, Meshack BM, Hillis LD, Peshock RM. Magnetic resonance imaging assessment of the severity of mitral regurgitation: Comparison with invasive techniques. Circulation. 1995;92:1151-1158.
10. Martin ET, Fuisz AR, Pohost GM. Imaging cardiac structure and pump function. Cardiol Clin. 1998;16:135-160. (Pubitemid 28249197)
11. Gerber BL, Rochitte CE, Bluemke DA, Melin JA, Crosille P, Becker LC, Lima JA. Relation between Gd-DTPA contrast enhancement and regional inotropic response in the periphery and center of myocardial infarction. Circulation. 2001;104:998-1004. (Pubitemid 32803875)
12. Olson HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol. 1974;77:439-454.
13. Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd RM. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation. 2001;104:1101-1107. (Pubitemid 32830391)
14. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep. 1978;62:955-961. (Pubitemid 8377895)
15. Messroghli DR, Niendorf T, Schulz-Menger J, Dietz R, Friedrich MG. T1 mapping in patients with acute myocardial infarction. J Cardiovasc Magn Reson. 2003;5:353-359. (Pubitemid 36569954)
16. Thompson RC, Canby RC, Lojeski EW, Ratner AV, Fallon JT, Pohost GM. Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties. Am Heart J. 1987;113:1444-1449. (Pubitemid 17092817)
17. Cottin Y, Ribuot C, Maupoil V, Godin D, Arnould L, Brunotte F, Rochette L. Early incidence of adriamycin treatment on cardiac parameters in the rat. Can J Physiol Pharmacol. 1994;72:140-145. (Pubitemid 24156228)
18. Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J. 2001;141:1007-1013. (Pubitemid 32477014)
19. Yilmaz S, Atessahin A, Sahna E, Karahan I, Ozer S. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology. 2006;218:164-171. (Pubitemid 41821347)
20. Herman EH, Ferrans VJ. Animal models of anthracycline cardiotoxicity: Basic mechanisms and cardioprotective activity. Prog Pediatr Cardiol. 1998;8:49-58. (Pubitemid 28181884)